NEC's Oral Cancer Vaccine NECVAX-NEO1 Shows Promise in Phase 1 Trial
• NEC Bio Therapeutics' NECVAX-NEO1, combined with checkpoint inhibitors, demonstrates encouraging interim results in a Phase 1 trial for solid tumors.
• The personalized, bacteria-based oral DNA vaccine induced an ELISPOT response in 68% of neoepitopes, with 40% of patients showing significant neoantigen-specific signals.
• After 24 weeks, 80% of patients treated with NECVAX-NEO1 achieved stable disease status, indicating a high disease control rate in melanoma, renal cell, and head and neck cancer patients.
• The Phase 1 trial showed no treatment-related toxicities, supporting further investigation of NECVAX-NEO1 as a potential treatment option for difficult-to-treat cancers.
Transgene and NEC's TG4050 Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• TG4050, an individualized immunotherapy, demonstrates 100% disease-free survival at 24.1 months in head and neck cancer patients after standard adjuvant therapy.
• The neoantigen cancer vaccine induced immune responses targeting selected neoantigens in all treated patients, showing strong and sustained immunogenicity.
• The ongoing Phase I/II trial is expanding internationally, with Phase II currently enrolling patients to further confirm these promising findings.
• TG4050 combines Transgene's myvac platform with NEC's AI to personalize cancer treatment by stimulating the immune system against tumor-specific mutations.
Transgene and NEC's TG4050 Cancer Vaccine Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• TG4050, an individualized immunotherapy, demonstrates a 100% disease-free rate in head and neck cancer patients after a median follow-up of 24.1 months.
• The Phase I trial data highlights the vaccine's strong immunogenicity, with immune responses targeting selected neoantigens observed in all patients.
• The ongoing trial has been expanded to a Phase I/II study to further evaluate TG4050's efficacy in preventing relapse in this high-risk patient population.
• TG4050 leverages Transgene's myvac® platform and NEC's AI to optimize antigen selection, offering a personalized approach to cancer treatment.
TG4050 Neoantigen Vaccine Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• A Phase I trial of TG4050 in head and neck cancer showed that all patients treated with the vaccine after standard care remained disease-free after 24.1 months.
• The individualized immunotherapy induced specific and sustained immune responses against selected neoantigens in all treated patients, demonstrating strong immunogenicity.
• Based on these promising results, the trial has been expanded into a Phase I/II study, with the Phase II portion currently enrolling patients internationally.
• The neoantigen cancer vaccine TG4050 demonstrates potential to prevent relapse in patients with locally advanced resected head and neck squamous cell carcinoma (HNSCC).
© Copyright 2025. All Rights Reserved by MedPath